Acute On Chronic Liver Failure (ACLF) Market Analysis, Market Size, Epidemiology, Leading Companies

Acute On Chronic Liver Failure (ACLF) Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight (Albany, US) DelveInsight has launched a new report on "Acute On Chronic Liver Failure (ACLF) Market Insights, Epidemiology, and Market Forecast-2030".

DelveInsight's "Acute On Chronic Liver Failure (ACLF) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Acute On Chronic Liver Failure (ACLF) , historical and forecasted epidemiology as well as the Acute On Chronic Liver Failure (ACLF) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the facts: 





Although a uniformly accepted definition for epidemiological studies is lacking, ACLF is the most life-threatening complication of cirrhosis. According to the US-national cohort study by Hernaez et al., of 72,316 patients hospitalized for decompensated cirrhosis, 26.4% (19,082) patients met the criteria of ACLF on admission. Of these, 12.8% had one, 10.1% had two, and 3.5% had three or more organ failures, respectively.

Europe-based study analyzed the data from 1343 patients with cirrhosis and acute liver decompensation. The study reported a prevalence of ACLF as 30.9% and was associated with a short-term (28-day) mortality, i.e., 15 times higher than in cirrhotic patients without ACLF. (Moreau et al.)

According to the study in Italy by Piano et al., it has been observed that among the 466 patients with cirrhosis, 118 patients (25%) were reported to develop ACLF, in which the number of patients 57; 33; and 28 belonged to grade-1, grade-2, and grade-3 ACLF, respectively. The study concluded that outpatients with cirrhosis have a high risk of developing ACLF.

View Report: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclfmarket Request Sample: https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failureaclf-market Scope of the Report



 

 

The report covers the descriptive overview of Acute On Chronic Liver Failure (ACLF) , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies Comprehensive insight has been provided into the Acute On Chronic Liver Failure (ACLF) epidemiology and treatment in the 7MM Additionally, an all-inclusive account of both the current and emerging therapies for Acute On Chronic Liver Failure (ACLF) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape A detailed review of Acute On Chronic Liver Failure (ACLF) market; historical and forecasted is included in the report, covering drug outreach in the 7MM The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acute On Chronic Liver Failure (ACLF) market

View Report: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclfmarket Request Sample: https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failureaclf-market The term ACLF was first introduced in 1995 to describe a condition in which two “lesions” or “insults” act simultaneously on the liver, one of which is chronic and the other is acute. However, the universally accepted and used definition of ACLF is still lacking. Therefore, several definitions have been developed by expert groups from the American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), and Asian-Pacific Association for the Study of the Liver (APASL).

According to AASLD and EASL working group ACLF is, “Acute deterioration of pre-existing chronic liver disease usually related to a precipitating event and associated with increased mortality at 3months due to multi-system organ failure”.On the other hand, the group of experts from APASL define the ACLF as, “Acute liver injury manifesting as jaundice (serum bilirubin ≥5 mg/dL) and coagulopathy (INR ≥1.5 or prothrombin activity of <40%), complicated within 4 weeks by ascites and/or encephalopathy in a patient previously diagnosed or undiagnosed chronic liver diseases.”

Organ failure is a major factor in the clinical course of ACLF. Moreover, the presence of hepatic encephalopathy (HE) within 4 weeks is part of the criteria for defining acute-on-chronic liver failure (ACLF).

It can be due to hepatotropic or non-hepatotropic agents/causes. Major etiologic agents responsible for precipitating ACLF are Hepatotropic viral infections, such as Hepatitis B virus, infection and superinfection with HEV, etc., and Non-hepatotropic insults, like surgery, trauma, and viral infections if producing direct hepatic insult could lead to ACLF. View Report: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclfmarket Request Sample: https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failureaclf-market Some of the Companies:  

Grifols Therapeutics Promethera Biosciences

  

Umecrine Cognition RHEACELL And Many Others

Drugs Covered:    

Albutein 5% (also known as PE-A 5%) HepaStem GR3027 And Many Others

View Report: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclfmarket Request Sample: https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failureaclf-market Key Questions Market Insights: 

What was the Acute On Chronic Liver Failure (ACLF) market share (%) distribution in 2017 and how it would look like in 2030?



What would be the Acute On Chronic Liver Failure (ACLF) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?



What are the key findings pertaining to the market across 7MM and which country will have the largest Acute On Chronic Liver Failure (ACLF) market size during the forecast period (2017-2030)?



At what CAGR, the Acute On Chronic Liver Failure (ACLF) market is expected to grow in 7MM during the forecast period (2017-2030)?



What would be the Acute On Chronic Liver Failure (ACLF) market outlook across the 7MM during the forecast period (2017-2030)?



What would be the Acute On Chronic Liver Failure (ACLF) market growth till 2030, and what will be the resultant market Size in the year 2030?



How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights: 

What is the disease risk, burden and unmet needs of the Acute On Chronic Liver Failure (ACLF) ?



What is the historical Acute On Chronic Liver Failure (ACLF) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?



What would be the forecasted patient pool of Acute On Chronic Liver Failure (ACLF) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?



What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Acute On Chronic Liver Failure (ACLF) ?



Out of all 7MM countries, which country would have the highest prevalent population of Acute On Chronic Liver Failure (ACLF) during the forecast period (2017-2030)?



At what CAGR the population is expected to grow in 7MM during the forecast period (20172030)?

View Report: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclfmarket Request Sample: https://www.delveinsight.com/sample-request/acute-on-chronic-liverfailure-aclf-market